Joseph Papa confirms position day after he resigns from the top spot at drugmaker Perrigo

Iseq rises as stocks on Wall Street and in Europe lifted by energy companies

Canadian pharma company says it remains well positioned to meet its obligations

New rules on corporate inversions see parties turn their attention elsewhere

Sprout shareholders say company has set price too high, not marketing pill properly

Pharmaceutical giant faces a growing list of questions from investors and regulators

Company has appointed activist investor William Ackman to its board

The Canadian drugmaker cut its 2016 forecast by about 12% causing shares to plunge

Iseq ends lower with Bank of Ireland, Applegreen and Aryzta among the fallers

Canadian drugmaker cuts its revenue forecast by 12% and raises the spectre of default

Deb Jorn oversaw the Canadian pharmaceutical’s US dermatology business

News comes as Canadian drug-maker pulled 2016 forecasts

Chief executive back at the helm after two-month absence through illness but Robert Ingram retains chairman’s post

First damages award over claims firm knew of ovarian cancer risks decades ago, company still faces 1,200 suits

Wall Street Journal reports that pharmaceutical firm plans to restate earnings

Hospitalisation of Mike Pearson saw firm split his roles and bring Ingram to the chair

Pershing Square Capital increased stake in beleaguered drug group last November but acts to generate tax loss for investors

Pharma companies’ method of buying drug makers and racking up costs is a threat to R&D

Food group Aryzta’s shares drop again in Dublin following boardroom reshuffle

Eye-popping growth and questionable acquisitions raise far too many questions

ECB president’s signal that stimulus will continue gives boost to markets

Valeant Pharmaceuticals shares shed a further $4.30, or 2.58 per cent

Treatment for parasitic infection a ‘bargain’ at $750 a tablet, says company executive

Deal comes days after final US approval for controversial drug

Fast-growing company loses CFO Howard Schiller as it looks to address issues with $11bn Salix Pharma acquisition

Mylan adopts poison-pill defence and renews commitment to Perrigo deal

European stock markets continue to enjoy lift from ECB’s quantitative easing

Pharma group accepts higher bid as Dublin based bidder Endo withdraws

Contact lens maker is to invest €41m in its Waterford facility over the next 18 months

Largest M&A deal of 2014 sees off hostile attention from rival Valeant

Actavis rumoured to be going head-to-head with rival Valeant for botox and eyecare group

Pharmaceutical firm’s offer values the Botox maker at $53bn

Shareholders are looking at alternative strategies for Allergan as it tries to fend off a deal from Valeant

Share price represents premium of 55 per cent

Botox maker’s board faces credibility problem, says ISS

Late afternoon sell-off sees Bank of Ireland shares fall more than 4%

Company announces $475 million restructuring meant to boost profits over six years

Migraine inhaler fails to secure go-ahead, with FDA citing delivery issues

Cantillon: few ‘clean hands’ in investment banking

Valeant Pharmaceuticals is a drug company that doesn’t develop drugs – it runs a serial takeover operation